PCM
MDGL icon

Penn Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Penn Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Sell
2,811
-699
-20% -$358K 0.1% 106
2026
Q1 		$1.87M Buy
3,510
+608
+21% +$290K 0.14% 93
2025
Q4 		$1.72M Buy
+2,902
New +$1.48M 0.14% 101

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Penn Capital Management's MDGL Position: Q2 2026 in Review

Penn Capital Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 20% in Q2 2026, selling an estimated $358K and leaving 2,811 shares worth $1.53M. The position accounts for 0.1% of the portfolio, ranked #106.

Penn Capital Management first reported a position in MDGL in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.87M in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Penn Capital Management held 2,811 shares of Madrigal Pharmaceuticals worth $1.53M as of Q2 2026.
  • Penn Capital Management sold 699 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $358K.
  • Madrigal Pharmaceuticals made up 0.1% of Penn Capital Management's portfolio in Q2 2026, its #106 holding.
  • Penn Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Penn Capital Management's Madrigal Pharmaceuticals position peaked at $1.87M in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Penn Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.